The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training ELIZABETH M. NIELSON and JEFFREY GUSS Journal of Psychedelic Studies, 2018 DOI: 10.1556/2054.2018.009 Abstract Clinical research on psychedelic-assisted psychotherapy is rapidly advancing in the USA, with two drugs, psilocybin and MDMA, progressing through a structure of FDA-approved trials on a trajectory toward Drug Enforcement Agency rescheduling for therapeutic use. Researcher’s and clinician’s personal use of psychedelics was cited as a potential confound in psychedelic research studies conducted in the 1950s and 1960s, a concern which contributed to the cessation of this research for some 20 years. Currently, there is no [...]
Lire la suiteEDITORIAL Should addiction researchers be interested in psychedelic science ? Stephen Bright, Martin Williams & David Caldicott Australasian Professional Society on Alcohol and other Drugs, Drug and Alcohol Review, 2017 DOI: 10.1111/dar.12544 As recently noted by Strauss, Bright and Williams [1], while much of the Western world has been experiencing a renaissance in research into ‘psychedelic science’ over the past decade [2], there has been no such research conducted in Australia. In Europe and the USA, studies have been conducted into lysergic acid diethylamide (LSD) that have improved our understanding of brain function [3] and reduced existential anxiety associated with dying [4], while psilocybin-assisted psychotherapy has [...]
Lire la suiteREBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics R. L. Carhart-Harris and K. J. Friston Pharmacological Reviews, 2019, 71, 316–344 https://doi.org/10.1124/pr.118.017160 Significance Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317 I. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . [...]
Lire la suiteSpectral signatures of serotonergic psychedelics and glutamatergic dissociatives Carla Pallavicini, Martina G. Vilas, Mirta Villarreal, Federico Zamberlan, Suresh Muthukumaraswamy, David Nutt, Robin Carhart-Harris, Enzo Tagliazucchi NeuroImage, 2019 https://doi.org/10.1016/j.neuroimage.2019.06.053 Abstract Classic serotonergic psychedelics are remarkable for their capacity to induce reversible alterations in consciousness of the self and the surroundings, mediated by agonism at serotonin 5-HT2A receptors. The subjective effects elicited by dissociative drugs acting as N-methyl-D-aspartate (NMDA) antagonists (e.g. ketamine and phencyclidine) overlap in certain domains with those of serotonergic psychedelics, suggesting some potential similarities in the brain activity patterns induced by both classes of drugs, despite different pharmacological mechanisms of action. We investigated source-localized [...]
Lire la suiteDisruptive Psychopharmacology Boris D. Heifets, MD, PhD1; Robert C. Malenka, MD, PhD2 JAMA Psychiatry. Published online June 26, 2019. doi:10.1001/jamapsychiatry.2019.1145 The paucity of medications with novel mechanisms for the treatment of mental illnesses combined with the delayed response to currently available medications has led to great excitement about the potential therapeutic utility of previously demonized drugs, which offer the hope of generating rapid symptom reductions in some of the sickest patients. Within the past 2 years, the US Food and Drug Administration approved esketamine for treatment-resistant depression and 2 compounds that are still on the US Drug Enforcement Administration’s most restrictive schedule, 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, [...]
Lire la suiteDynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin Louis-David Lord, Paul Expert, Selen Atasoy, Leor Roseman, Kristina Rapuano, Renaud Lambiotte, David J. Nutt, Gustavo Deco, Robin L. Carhart-Harris, Morten L. Kringelbach, Joana Cabral, NeuroImage, 2019, 199, 127–142 https://doi.org/10.1016/j.neuroimage.2019.05.060 A B S T R A C T Growing evidence from the dynamical analysis of functional neuroimaging data suggests that brain function can be understood as the exploration of a repertoire of metastable connectivity patterns (‘functional brain networks’), which potentially underlie different mental processes. The present study characterizes how the brain's dynamical exploration of resting-state networks is rapidly modulated by intravenous [...]
Lire la suitePilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano and Roland R Griffiths Journal of Psychopharmacology, 2014, Vol. 28(11) 983–992 © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881114548296 Abstract Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an openlabel pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment [...]
Lire la suiteCessation and reduction in alcohol consumption and misuse after psychedelic use Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths and Matthew W Johnson Journal of Psychopharmacology, 2019, 1–14 DOI: 10.1177/0269881119845793 journals.sagepub.com/home/jop Abstract Background : Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders. Aims : To supplement clinical studies, reports of psychedelic use in naturalistic settings can provide further data regarding potential effects of psychedelics on alcohol use. Methods [...]
Lire la suiteCurrent perspectives on psychedelic therapy : use of serotonergic hallucinogens in clinical interventions Albert Garcia-Romeu and William A. Richards Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA INTERNATIONAL REVIEW OF PSYCHIATRY, 2018 https://doi.org/10.1080/09540261.2018.1486289 ABSTRACT Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20th century, considerable advances were made in developing therapeutic approaches integrating administration of low (psycholytic) and high (psychedelic) doses of serotonergic hallucinogens for treatment [...]
Lire la suiteLa psychothérapie psychédélique est de retour M le magazine du Monde | 12.03.2015 Mescaline, ecstasy, psilocybine soigneront-ils la dépression, l’angoisse, l’autisme ou l’alcoolisme ? Des psychiatres américains explorent le potentiel thérapeutique de ces substances illicites. Par Stéphanie Chayet Engourdissement, d’abord. Puis grande fatigue, bâillements. Des images, très abstraites, comme de l’art moderne. Des motifs. Image d’un chat en train de mordiller le câble de freinage d’un vélo. Après ça ? Sentiment de ne pas m’aimer. Pas du tout. Puis je me demande : pourquoi je ne m’aimerais pas ? Il n’y a aucune raison. » Ainsi commence, mot pour mot, le « compte rendu d’expérience [...]
Lire la suite